AMGA President, CEO Donald Fisher dies of cancer

The American Medical Group Association (AMGA) announced that its longtime president and CEO, Donald Fisher, PhD, died of cancer on March 26.

Fisher, 71, had been in charge of the organization since 1980, when it was known as AGPA. The organization called him a “strong advocate for multispecialty medical groups and other organized systems of care and for the patients served by these systems,” helping to expand AMGA from 7,000 members when he took over to more than 175,000 today.

“Don leaves a professional and personal legacy that is not bound by time or physical space,” Donn Sorensen, chair of the AMGA Board of Directors, said in a statement. “His dedication to advancing the best possible patient care, to leading with integrity, and to building a great place to work, not forgetting to have a little fun while accomplishing much, have made a permanent mark on the hearts of all who knew him. We will miss him greatly.”

Fisher earned a BS in biology/chemistry from Millsaps College in 1968, his MS in anatomy from the University of Mississippi, School of Medicine in 1971 and a PhD in anatomy from the University of Mississippi in 1973, according to AMGA. Before serving as the group’s director for nearly 37 years, he was the first executive director for the American Academy of Physician Assistants. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.